<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450540</url>
  </required_header>
  <id_info>
    <org_study_id>AR-1112-AGPAP-MS</org_study_id>
    <nct_id>NCT01450540</nct_id>
  </id_info>
  <brief_title>Automated Graduated CPAP (AGPAP) for Improved Adherence in Newly Diagnosed Obstructive Sleep Apnea (OSA) Patients</brief_title>
  <official_title>Automated Graduated CPAP (AGPAP) for Improved Adherence in Newly Diagnosed OSA Patients: Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philips Respironics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philips Respironics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although positive airway pressure (PAP) is a highly effective treatment for sleep apnea,&#xD;
      adherence to therapy remains an obstacle. Automated Graduated CPAP (AGPAP), also know as&#xD;
      EZ-start, is an extended duration ramp, where the patient receives pressure below their&#xD;
      prescription during an acclimation phase. The algorithm gradually increases pressure to&#xD;
      therapy level based on usage. The aim of this study was to determine the effectiveness of the&#xD;
      AGPAP acclimation period and its impact on short term adherence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Even though CPAP is highly effective in treating sleep apnea, adherence to CPAP therapy&#xD;
      remains the largest single obstacle to the successful resolution of sleep-disordered&#xD;
      breathing in OSA patients. It has been estimated that up to 50% of patients who have been&#xD;
      prescribed CPAP for Obstructive Sleep Apnea (OSA) are not using the treatment one year later.&#xD;
      A myriad of possible causes for low compliance rates have been proposed and examined in&#xD;
      previous studies. These include race, gender, education level, income, bed-partner's sleep&#xD;
      quality, mask discomfort, continuity of care, nasal irritation, discomfort due to elevated&#xD;
      expiratory pressure, and level of daytime sleepiness.&#xD;
&#xD;
      Therefore, many investigators have proposed new methods and approaches to help deal with&#xD;
      these problems. Interventions have ranged from people-centric approaches using intensive CPAP&#xD;
      education and follow-up programs, to device modifications using features such as a ramp,&#xD;
      C-FLEX®, BiLevel therapy, and heated humidification.&#xD;
&#xD;
      In this study. The aim of this study was to determine the effectiveness of the Automated&#xD;
      Graduated CPAP (AGPAP), also know as EZ-start acclimation period, and its impact on short&#xD;
      term adherence&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CPAP Adherence</measure>
    <time_frame>3 months</time_frame>
    <description>Device usage (hours per night)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Outcome Sleep Quality (FOSQ)</measure>
    <time_frame>3 months</time_frame>
    <description>Functional Outcomes Sleep Questionnaire (FOSQ) is a self-administered instrument designed to assess the impact of excessive sleepiness on daytime function and to quantify improvement after treatment. It contains 30 items divided into 5 subscales: Activity level, vigilance, intimacy and sexual relationships, general productivity, and social outcome. The patient rates the difficulty of performing a given activity on a 4-point scale (no difficulty to extreme difficulty) A mean score is calculated for each scale ranging from 0 (maximum functional impact) to 24 (no functional impact).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime Sleepiness as Measured by the Epworth Sleepiness Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The ESS score can range from 0 to 24. The higher the ESS score, the higher is the overall 'daytime sleepiness'.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>REMStar auto A-Flex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modified REMstar Auto A-Flex with AGPAP</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>REMstar Auto A-Flex</intervention_name>
    <description>Standard CPAP</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Philips Respironics System One</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>modified REMstar Auto A-Flex with AGPAP</intervention_name>
    <description>Modified device -Software upgrade to GP 12</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Philips Respironics System One</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed with OSA (last 12 weeks)&#xD;
&#xD;
          -  Prescribed continuous positive airway pressure (CPAP) pressure ≥ 10 cmH2O&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  Able to follow instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another interventional research study within the last 30 days&#xD;
&#xD;
          -  Major controlled or an uncontrolled medical condition such as congestive heart&#xD;
             failure, neuromuscular disease, renal failure, cancer, chronic obstructive pulmonary&#xD;
             disease (COPD), respiratory failure or insufficiency, or patients requiring oxygen&#xD;
             therapy (as determined by self-report and reviewed by the study PI.)&#xD;
&#xD;
          -  Prior PAP prescription, use, or any prior OSA treatment, excluding split-night or&#xD;
             titration PAP exposure.&#xD;
&#xD;
          -  Prescribed BiLevel therapy&#xD;
&#xD;
          -  Presence of untreated, non-OSA related sleep disorders (e.g. moderate to severe&#xD;
             restless legs (PLMAI ≥ 20) or insomnia)&#xD;
&#xD;
          -  History of an automobile accident or near accident in the last 12 months due to&#xD;
             sleepiness.&#xD;
&#xD;
          -  Severe oxygen desaturation on the PSG (Sa02 &lt; 70% for 10% of the diagnostic PSG&#xD;
             study).&#xD;
&#xD;
          -  Surgery of the upper airway, nose, sinus, or middle ear within the past 90 days&#xD;
&#xD;
          -  Regular use (&gt;3 nights per week) of sleeping pills or stimulants.&#xD;
&#xD;
          -  Currently working a night shift or rotating day/night shift.&#xD;
&#xD;
          -  Unwillingness to try PAP at home.&#xD;
&#xD;
          -  Presence of tracheostomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Lankford, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sleep Disorders Center of Georgia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Delta Waves Sleep Disorder and Research Center</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Disorders Center of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clayton Sleep Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinilabs, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Therapy and Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 7, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2011</study_first_posted>
  <results_first_submitted>October 19, 2020</results_first_submitted>
  <results_first_submitted_qc>February 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2021</results_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>REMStar auto A-Flex&#xD;
REMstar Auto A-Flex: Standard CPAP</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>modified REMstar Auto A-Flex with AGPAP&#xD;
modified REMstar Auto A-Flex with AGPAP: Modified device -Software upgrade to GP 12</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>241 participants were enrolled in the trial and randomized, 123 in group 1 and 118 in group 2. there were 3 protocol deviations in group 1 and 23 deviations in group 2. data from these participants were excluded from the final analysis as per the statistical plan, and an intention to treat analysis was performed.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>REMStar auto A-Flex&#xD;
REMstar Auto A-Flex: Standard CPAP</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>modified REMstar Auto A-Flex with AGPAP&#xD;
modified REMstar Auto A-Flex with AGPAP: Modified device -Software upgrade to GP 12</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="235"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" spread="10.5"/>
                    <measurement group_id="B2" value="46.2" spread="11.0"/>
                    <measurement group_id="B3" value="47.3" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apnea-hypopnea index (AHI)</title>
          <units>events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="34.6"/>
                    <measurement group_id="B2" value="42.2" spread="31.1"/>
                    <measurement group_id="B3" value="43.4" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CPAP Prescription</title>
          <units>cmH2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.1" spread="2.1"/>
                    <measurement group_id="B2" value="12.3" spread="2.2"/>
                    <measurement group_id="B3" value="12.2" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Functional Outcomes Sleep Questionnaire (FOSQ) (quality of life questionnaire</title>
          <description>Functional Outcomes Sleep Questionnaire (FOSQ) is a self-administered instrument designed to assess the impact of excessive sleepiness on daytime function and to quantify improvement after treatment. It contains 30 items divided into 5 subscales: Activity level, vigilance, intimacy and sexual relationships, general productivity, and social outcome. The patient rates the difficulty of performing a given activity on a 4-point scale (no difficulty to extreme difficulty)&#xD;
A mean score is calculated for each scale ranging from 0 (maximum functional impact) to 24 (no functional impact).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" spread="0.6"/>
                    <measurement group_id="B2" value="2.8" spread="0.7"/>
                    <measurement group_id="B3" value="2.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epworth Sleepiness Scale</title>
          <description>Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The ESS score can range from 0 to 24. The higher the ESS score, the higher is the overall 'daytime sleepiness'.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.2" spread="4.6"/>
                    <measurement group_id="B2" value="11.6" spread="5.1"/>
                    <measurement group_id="B3" value="11.9" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CPAP Adherence</title>
        <description>Device usage (hours per night)</description>
        <time_frame>3 months</time_frame>
        <population>241 participants were enrolled in the trial and randomized, group 1 = 123 and group 2 = 118. There were 3 protocol deviations in group 1 and 23 deviations in group 2. Data from these participants were excluded from the final analysis as per the statistical plan, and an intention to treat analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>REMStar auto A-Flex&#xD;
REMstar Auto A-Flex: Standard CPAP</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>modified REMstar Auto A-Flex with AGPAP&#xD;
modified REMstar Auto A-Flex with AGPAP: Modified device -Software upgrade to GP 12</description>
          </group>
        </group_list>
        <measure>
          <title>CPAP Adherence</title>
          <description>Device usage (hours per night)</description>
          <population>241 participants were enrolled in the trial and randomized, group 1 = 123 and group 2 = 118. There were 3 protocol deviations in group 1 and 23 deviations in group 2. Data from these participants were excluded from the final analysis as per the statistical plan, and an intention to treat analysis was performed.</population>
          <units>hours per night</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="2.5"/>
                    <measurement group_id="O2" value="4.0" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Outcome Sleep Quality (FOSQ)</title>
        <description>Functional Outcomes Sleep Questionnaire (FOSQ) is a self-administered instrument designed to assess the impact of excessive sleepiness on daytime function and to quantify improvement after treatment. It contains 30 items divided into 5 subscales: Activity level, vigilance, intimacy and sexual relationships, general productivity, and social outcome. The patient rates the difficulty of performing a given activity on a 4-point scale (no difficulty to extreme difficulty) A mean score is calculated for each scale ranging from 0 (maximum functional impact) to 24 (no functional impact).</description>
        <time_frame>3 months</time_frame>
        <population>241 participants were enrolled in the trial and randomized, group 1 = 123 and group 2 = 118. There were 3 protocol deviations in group 1 and 23 deviations in group 2. Data from these participants were excluded from the final analysis as per the statistical plan, and an intention to treat analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1- Standard CPAP</title>
            <description>REMStar auto A-Flex&#xD;
REMstar Auto A-Flex: Standard CPAP</description>
          </group>
          <group group_id="O2">
            <title>Group 2 -AGPAP</title>
            <description>modified REMstar Auto A-Flex with AGPAP&#xD;
modified REMstar Auto A-Flex with AGPAP: Modified device -Software upgrade to GP 12</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Outcome Sleep Quality (FOSQ)</title>
          <description>Functional Outcomes Sleep Questionnaire (FOSQ) is a self-administered instrument designed to assess the impact of excessive sleepiness on daytime function and to quantify improvement after treatment. It contains 30 items divided into 5 subscales: Activity level, vigilance, intimacy and sexual relationships, general productivity, and social outcome. The patient rates the difficulty of performing a given activity on a 4-point scale (no difficulty to extreme difficulty) A mean score is calculated for each scale ranging from 0 (maximum functional impact) to 24 (no functional impact).</description>
          <population>241 participants were enrolled in the trial and randomized, group 1 = 123 and group 2 = 118. There were 3 protocol deviations in group 1 and 23 deviations in group 2. Data from these participants were excluded from the final analysis as per the statistical plan, and an intention to treat analysis was performed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="0.68"/>
                    <measurement group_id="O2" value="3.25" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Sleepiness as Measured by the Epworth Sleepiness Scale</title>
        <description>Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The ESS score can range from 0 to 24. The higher the ESS score, the higher is the overall 'daytime sleepiness'.</description>
        <time_frame>3 months</time_frame>
        <population>241 participants were enrolled in the trial and randomized, group 1 = 123 and group 2 = 118. There were 3 protocol deviations in group 1 and 23 deviations in group 2. Data from these participants were excluded from the final analysis as per the statistical plan, and an intention to treat analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1- Standard CPAP</title>
            <description>REMStar auto A-Flex&#xD;
REMstar Auto A-Flex: Standard CPAP</description>
          </group>
          <group group_id="O2">
            <title>Group 2 -AGPAP</title>
            <description>modified REMstar Auto A-Flex with AGPAP&#xD;
modified REMstar Auto A-Flex with AGPAP: Modified device -Software upgrade to GP 12</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Sleepiness as Measured by the Epworth Sleepiness Scale</title>
          <description>Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The ESS score can range from 0 to 24. The higher the ESS score, the higher is the overall 'daytime sleepiness'.</description>
          <population>241 participants were enrolled in the trial and randomized, group 1 = 123 and group 2 = 118. There were 3 protocol deviations in group 1 and 23 deviations in group 2. Data from these participants were excluded from the final analysis as per the statistical plan, and an intention to treat analysis was performed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.05" spread="4.45"/>
                    <measurement group_id="O2" value="8.27" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the device trial period, e.g. 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1- Standard CPAP</title>
          <description>REMStar auto A-Flex&#xD;
REMstar Auto A-Flex: Standard CPAP</description>
        </group>
        <group group_id="E2">
          <title>Group 2 -AGPAP</title>
          <description>modified REMstar Auto A-Flex with AGPAP&#xD;
modified REMstar Auto A-Flex with AGPAP: Modified device -Software upgrade to GP 12</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Participant 404 was hospitalized with complaints of dizziness and light-headed. The report obtained from the Hospital lists subconjunctival hemorrhage, severe uncontrolled hypertension, and uncontrolled diabetes as the main findings</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Bipolar manic episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Worsening of hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aerophagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Upset stomach and diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>cracked dental implant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>MRSA in armpit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <description>Broken &amp; casted R carpal, 5th digit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Ankle swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dry, Stuffy Nose or Nosebleeds, skin irritation</sub_title>
                <description>These are common side effects of CPAP therapy. https://www.sleepassociation.org/sleep-apnea/cpap-treatment/cpap-side-effects/</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cold/flu symptoms</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Bronchites/asthma exacerbation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Data Scientist</name_or_title>
      <organization>Philips</organization>
      <phone>+14125423651</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

